肺免疫预后指数与晚期非小细胞肺癌免疫检查点抑制剂疗效的相关性
多中心回顾性研究在8个欧洲中心纳入测试集161例和验证集305例接受PD-1/PD-L1抑制剂治疗的晚期NSCLC患者,并设化疗对照组162例。基于dNLR>3和LDH>ULN构建LIPI,分为良好、中间、不良三组。汇总ICI队列466例中,LIPI不良组中位OS仅3个月、良好组34个月,PFS分别为2.0和6.3个月(均P<.001);该关联在验证集可重复,化疗组无统计学意义。
要点
- 治疗前dNLR>3和LDH>ULN是ICI治疗患者OS的独立不良因素。
- LIPI不良组中位OS为3个月,良好组为34个月(P<.001)。
- LIPI与ICI疗效相关,但与化疗疗效无关,或可辅助筛选ICI获益人群。
核心结论
- 治疗前LIPI(dNLR>3且LDH>ULN)与ICI治疗的不良结局相关,但与化疗无关,提示LIPI可能有助于识别不太可能从ICI治疗中获益的患者。
研究设计与样本
- 多中心回顾性研究,包括测试集161例、验证集305例接受PD-1/PD-L1抑制剂治疗的患者(8个欧洲中心),以及化疗对照组162例。
- 基于dNLR>3和LDH>ULN构建LIPI,分为良好(0个因素)、中间(1个因素)、不良(2个因素)三组。
- 主要终点为总生存期(OS),次要终点为无进展生存期(PFS)和疾病控制率(DCR)。
主要发现
- 在测试集中,dNLR>3和LDH>ULN分别与OS独立相关(HR 2.22;95%CI 1.23-4.01和HR 2.51;95%CI 1.32-4.76)。
- LIPI不良、中间、良好组的中位OS分别为3个月(95%CI 1个月-NR)、10个月(95%CI 8个月-NR)和34个月(95%CI 17个月-NR)。
- LIPI不良、中间、良好组的中位PFS分别为2.0个月(95%CI 1.7-4.0)、3.7个月(95%CI 3.0-4.8)和6.3个月(95%CI 5.0-8.0)(均P<.001)。
- DCR也与dNLR>3和LDH>ULN相关;OS、PFS和DCR结果在ICI验证集中可重复,但在化疗队列中无统计学意义。
关键数值与推荐
- LIPI分组标准:dNLR>3和LDH>ULN各计1个因素;良好组0个因素,中间组1个因素,不良组2个因素。
- 测试集中位PFS为3个月(95%CI 2-4),中位OS为10个月(95%CI 8-13)。
临床怎么用
- 治疗前可计算LIPI(基于dNLR和LDH),辅助评估晚期NSCLC患者接受ICI治疗的预后风险。
- LIPI不良组患者ICI治疗预后较差,临床决策时可结合该指标综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) and lactate dehydrogenase (LDH) level have been correlated with immune checkpoint inhibitor (ICI) outcomes in patients with melanoma. OBJECTIVE: To determine whether pretreatment dNLR and LDH are associated with resistance to ICIs in patients with advanced non-small cell lung cancer (NSCLC). DESIGN, SETTING, AND PARTICIPANTS: Multicenter retrospective study with a test (n = 161) and a validation set (n = 305) treated with programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors in 8 European centers, and a control cohort (n = 162) treated with chemotherapy only. Complete blood cell counts, LDH, and albumin levels were measured before ICI treatment. A lung immune prognostic index (LIPI) based on dNLR greater than 3 and LDH greater than upper limit of normal (ULN) was developed, characterizing 3 groups (good, 0 factors; intermediate, 1 factor; poor, 2 factors). MAIN OUTCOMES AND MEASURES: The primary end point was overall survival (OS). Secondary end points were progression-free survival (PFS) and disease control rate (DCR). RESULTS: In the pooled ICI cohort (N = 466), 301 patients (65%) were male, 422 (90%) were current or former smokers, and 401 (87%) had performance status of 1 or less; median age at diagnosis was 62 (range, 29-86) years; 270 (58%) had adenocarcinoma and 159 (34%) had squamous histologic subtype. Among 129 patients with PD-L1 data, 96 (74%) had PD-L1 of at least 1% by immunohistochemical analysis, and 33 (26%) had negative results. In the test cohort, median PFS and OS were 3 (95% CI, 2-4) and 10 (95% CI, 8-13) months, respectively. A dNLR greater than 3 and LDH greater than ULN were independently associated with OS (hazard ratio [HR] 2.22; 95% CI, 1.23-4.01 and HR, 2.51; 95% CI, 1.32-4.76, respectively). Median OS for poor, intermediate, and good LIPI was 3 months (95% CI, 1 month to not reached [NR]), 10 months (95% CI, 8 months to NR), and 34 months (95% CI, 17 months to NR), respectively, and median PFS was 2.0 (95% CI, 1.7-4.0), 3.7 (95% CI, 3.0-4.8), and 6.3 (95% CI, 5.0-8.0) months (both P < .001). Disease control rate was also correlated with dNLR greater than 3 and LDH greater than ULN. Results were reproducible in the ICI validation cohort for OS, PFS, and DCR, but were nonsignificant in the chemotherapy cohort. CONCLUSIONS AND RELEVANCE: Pretreatment LIPI, combining dNLR greater than 3 and LDH greater than ULN, was correlated with worse outcomes for ICI, but not for chemotherapy, suggesting that LIPI can serve as a potentially useful tool when selecting ICI treatment, raising the hypothesis that the LIPI might be useful for identifying patients unlikely to benefit from treatment with an ICI.
引用
- Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018. PMID: 29327044. doi:10.1001/jamaoncol.2017.4771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。